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Patient Perceptions of Allergic Rhinitis and Quality of Life
Findings From a Survey Conducted in Europe and the United States
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Background: Allergic rhinitis (AR) is a common, costly, and trou-
blesome condition, impairing patients’ quality of life (QoL),
cognitive function, and productivity. Patients with AR report dis-
turbed sleep, fatigue, irritability, and a range of practical problems.
However, there is a relative lack of data on how patients with AR
perceive their QoL.
Objective: To better understand how patients perceive AR and their
attitudes toward this condition (including QoL) and its treatment
options.
Methods: An online and telephone survey of 3635 people identiﬁed
as having outdoor and indoor allergies, urticaria, and/or pet allergies
was performed in 6 countries.
Results: The survey conﬁrmed that patients with allergies perceive
their symptoms as causing signiﬁcant disruptions to their daily lives.
Respondents were affected for a considerable part of each day, with
the most severe symptoms occurring in the morning. The most im-
portant desired effect of medication was the restoration of normal
breathing, and the most highly rated attributes of the Bideal[ AR drug
were efﬁcacy, safety, and freedom from undesirable side effects.
Conclusions: The information gathered from allergy sufferers who
participated in this survey sheds light on the degree to which people
with allergies are affected by their disease and the limitations imposed
by associated symptoms.
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In clinical trials of allergic rhinitis (AR), quality of life (QoL)is assessed by questionnaires that ask subjects about the
effects of AR on various domains of their daily lives, including
practical functions, social interactions, emotional well-being,
and economic activity. These instruments comprise both ge-
neric questionnaires that measure physical, mental, and psy-
chosocial functioning, such as the Medical Outcomes Study
36-Item Short-Form Health Survey,1,2 and ones that are more
disease speciﬁc, such as the Rhinoconjunctivitis Quality of
Life Questionnaire (RQLQ), Rhinasthma, and the Rhinosinu-
sitis Disability Index.3Y5 The effects of AR on health-related
QoL extend to learning, sleep, vitality/alertness, perception of
general health, cognitive and emotional functioning, and psy-
chomotor performance.6Y8 Strong, highly signiﬁcant correla-
tions have been found between clinical AR symptoms and
QoL.6 Such limitations on daily functioning can have negative
effects on a person’s performance at home, school, or work,
which have both a direct and an indirect economic impact on
society.9
An online survey conducted in 2004 to assess QoL in
2002 patients with AR and nasal congestion (or their care-
givers) has reinforced these ﬁndings.10 Within the subgroup
of working adults (n = 1043), 59% reported that their con-
gestion had affected their job performance. Of the 446
caregivers, 42% said that congestion led to their child’s poor
productivity in school. Nasal congestion associated with AR
also led to feelings of discomfort, frustration, fatigue, irri-
tability, and stress.10 A Swedish survey of 9538 adolescents
with AR and/or asthma found that severe nasal symptoms
were associated with lower grades in school.11
Although the typical clinical symptoms of AR might
be considered relatively inconsequential, they are consistently
mentioned by patients as having a signiﬁcant impact on QoL.
Thus, there may be a disconnect between clinicians’ percep-
tions of AR as a chronic but nonserious medical condition that
causes a limited range of symptoms and patients’ perceptions
of it as a limiting and disabling presence in their lives. This
disconnect may in turn lead to suboptimal treatment.
To address the way health care providers and patients
perceive the effects of AR, a multinational survey, BUnder-
standing the Dynamics of Allergy Suffering and Treatment,[
conducted by the Forbes Consulting Group, was undertaken.
The objective was to better understand patients’ attitudes and
perceptions about the symptoms and effects of AR, treatment
approaches, and available therapies. The survey investigated
respondents’ product or brand choices and what form of the-
rapy they preferred (eg, tablets, nasal sprays). Some method-
ologic ﬂexibility to deﬁne concepts was permitted within each
country.
METHODS
A questionnaire was administered in July 2005 to res-
pondents in France, Germany, Italy, Spain, the United
Kingdom, and the United States, with the goal of obtaining
a minimum of 575 complete responses from each country
(3450 total): 500 from people who treated their allergies and
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75 from nontreaters. The actual number of complete responses
received was 3635. Respondent panels were recruited in a way
that the geographic distribution of the panel within each coun-
try accurately reﬂected the population distribution.
The survey was conducted by Internet, except in Spain,
where it was conducted by telephone. To ensure uniformity of
responses and to control for scale-use bias, scale variables
were standardized, setting the mean within each variable and
within each observation to zero and the SD to 1. A follow-up
interview was conducted by Internet in the United States in
November 2005.
Respondents were included only if they had experienced
symptoms related to outdoor, indoor, pet, mold, or dust aller-
gies, including AR and urticaria, during the preceding
12 months. People who primarily had food, insect, or medica-
tion allergies were excluded.
Survey participants answered questions on the fre-
quency and duration of symptoms, the times of day and the
season(s) in which they occurred, and what types of symp-
toms they experienced. They were given a list of the core
allergy symptoms and were asked to note which ones they
had: sneezing, itchy/watery eyes, nasal congestion, runny
nose, sinus congestion, postnasal drip, sinus pressure, itchy
throat, sinus pain, and hives/rash. Patients were also asked to
use a list of 9 possible responses to rate the emotional impact
of their morning allergy symptoms: more irritable, more
fatigued, less motivated, less energetic, hard to concentrate,
more frustrated, less alert, more self-conscious, and feelings
not affected. There were questions about how disruptive nasal
allergies in general (and congestion speciﬁcally) were to
various aspects of everyday life, including sleep, participation
in social and outdoor activities, and mood. Data were weight-
ed to age, sex, and household income distributions. Respon-
dents in the United States were subdivided according to 3
levels of symptom severity (mild, moderate, and severe).
Lifestyle impact was calculated with index scores based
on symptoms and lifestyle disruption. The prevalence of spe-
ciﬁc symptoms was multiplied by symptom severity and was
indexed against the overall average to create individual index
scores for the various symptoms. Prevalence of lifestyle dif-
ﬁculties was multiplied by disruptiveness and was indexed
against the overall average to create individual scores.
RESULTS
Demographics
Respondent demographics are listed in Table 1. The
percentage of male patients was similar in the 6 countries, but
the survey participants’ ages and overall health varied among
the countries.
Incidence
There was considerable intercountry variability with
regard to the seasons in which AR was experienced. Forty-
four percent of respondents in the United States experienced
3- or 4-season allergies, followed by France (35%), Germany
(33%), and the United Kingdom (30%), with much lower in-
cidences reported in Italy (16%) and Spain (11%) (Fig. 1).

















48 47 49 49 48 49
Mean
age, yr
39 39 38 44 42 44
Overall
health, %
Excellent 8 3 6 9 8 9
Very good 30 26 30 17 31 39
Good 46 52 46 40 33 35
Fair 14 16 16 29 25 13
Poor 3 4 2 6 4 3
FIGURE 1. Number of seasons experiencing allergy symptoms.
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In most countries, the highest percentage of
respondents experienced allergy symptoms in the spring, led
by France (92%). The only exception was in the United
Kingdom, where the highest percentage (89%) reported al-
lergies during the summer (Fig. 2).
Respondents in the United States reported having the
greatest number of days experiencing allergy symptoms per
year (102), followed by the United Kingdom (79), Germany
(68), France (62), Italy (37), and Spain (33). Survey parti-
cipants in the United Kingdom reported the highest number of
annual days with indoor allergies (160), followed by the
United States (129), Germany (103), France (67), Italy (59),
and Spain (36).
The Allergic Rhinitis and its Impact on Asthma Work-
shop recommended that the terms seasonal and perennial AR
be replaced with intermittent AR (IAR) and persistent AR
(PER). Intermittent AR is deﬁned as the presence of rhinitis
symptoms for less than 4 days/wk or for less than 4 weeks,
whereas in PER, rhinitis symptoms are present for greater than
4 days/wk and for greater than 4 weeks.12 Table 2 lists the
distribution of patients with IAR and PER in the 6 study
countries. Spain had the most patients with IAR (70%),
whereas both the United Kingdom and the United States had
the greatest percentage of respondents with PER (53% and
52%, respectively). This is consistent with the number of
reported symptom days.
Diagnosis
Respondents’ rhinitis was largely self-diagnosed in all
countries surveyed, led by France (74%), followed by the
United States (72%), Germany (62%), the United Kingdom
(61%), Italy (60%), and Spain (50%). Spain reported the
highest percentage of physician diagnoses (46%), followed by
Italy (41%); only in France did less than one third of res-
pondents receive a physician diagnosis. The percentage of
respondents who were diagnosed by a friend or a family
member varied from 7% in Italy and Spain to 18% in the
United Kingdom and France. A negligible percentage was
diagnosed by other means; that is, pharmacist, homeopath,
physician’s assistant, nurse practitioner, or information ob-
tained in a physician’s ofﬁce or from an advertisement. (Res-
pondents could provide more than 1 answer to this question.)
Symptoms
A majority of respondents in all countries reported
sneezing and itchy/watery eyes to be their most common
symptoms (sneezing: 64%Y84%; itchy/watery eyes:
63%Y86%). Other symptoms elicited more varied responses.
For example, 66% of respondents in the United States reported
sinus congestion compared with only 12% of those in Spain
(Fig. 3).
There was a great amount of intercountry variability
between the number of participants reporting nasal and sinus
congestion and sinus pressure and pain. Nasal congestion was
by far the most common symptom across countries. The
percentage of positive responses to nasal congestion ranged
from 43% in France to 68% in the United States.
Patients in all countries reported that their most severe
symptoms occurred Bwhen I ﬁrst wake up in the morning[ or
Bat other times in the morning.[ Fifty-eight percent of res-
pondents in Spain and Italy identiﬁed the morning hours as the
time they experienced their worst allergic symptoms, followed
by France (51%), Germany (48%), and the United Kingdom
and the United States (both 46%). Lesser percentages were
noted for severe afternoon, evening, and nighttime allergies
(Fig. 4).
FIGURE 2. Time of year when allergy symptoms were experienced.
TABLE 2. Distribution of IAR and PER





IAR, % 50 52 64 70 47 48
PER, % 50 48 36 30 53 52
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However, the nature of morning symptoms varied. Res-
pondents in France and Spain identiﬁed sneezing as their most
frequent symptom upon rising (60%), whereas in the United
States it was nasal congestion (56%). More than half of
Spanish respondents experienced itchy eyes and runny nose
most frequently in the morning; Spain was the only country
that reported a 50% or greater response rate for both of these
symptoms.
Overall, US participants reported more negative emo-
tional effects from morning allergies than those surveyed in
the other 5 countries. In general, irritability and fatigue were
the most common effects of symptoms, with some variation
between the countries. Responders in Italy reported a higher
degree of irritability (58%), followed by the United States
(55%) and the United Kingdom (53%), compared with only
24% of responders in Spain. French participants noted the
highest degree of fatigue (59%), followed by the United States
(52%); it was identiﬁed as a primary morning concern by 31%
to 44% of patients in the other countries.
A large percentage of responders reported difﬁculty in
falling asleep without trouble, ranging from 47% in Spain to
26% in Germany and the United Kingdom. When respon-
dents were asked whether this problem was disruptive, 73% in
the United States, 71% in France, 68% in Germany, 57% in the
United Kingdom, and 52% in Italy said that it was; however,
only 24% of those in Spain (many of whom had reported
difﬁculty in falling asleep) said that it was disruptive (Fig. 5).
From a list of 12 topics on the impact of AR on lifestyle,
breathing normally was ranked as the ﬁrst and most common
difﬁculty across all countries (Table 3). The topic ranked last
in all countries was the impact on the ability to take care of
children. Overall, issues relating to sleep and rest were rated as
FIGURE 3. Allergy symptoms experienced.
FIGURE 4. Time of day when symptoms were most severe.
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more difﬁcult than issues relating to social interaction. There
was considerable divergence about the ability to participate in
outdoor activities.
Treatment Regimens
Despite the large rate of reported self-diagnoses, in all
countries the highest response to the question BWhy did you
ﬁrst try the product you use most often?[ was BDoctor
recommended/prescribed it.[ This was true for both prescrip-
tion (Rx) and over-the-counter (OTC) treatments, with the
highest percentage of drug choices based on physician
recommendation occurring in Spain (86% Rx; 76% OTC).
Spain (66%) and France (62%) had the highest rates of Rx
drug use, and the United Kingdom had the highest rate of OTC
drug use (41%).
In the United Kingdom, 23% of responders selected
their own medications regardless of physician input, and 28%
of those in this subgroup chose OTC formulations. Friends
and pharmacists were also identiﬁed as major inﬂuences in the
selection of OTC formulations, but they had a considerably
smaller inﬂuence on Rx drug choice. Advertising had some
inﬂuence when it came to patient choice of OTC medications
but was much less inﬂuential in Rx drug choice.
When questioned about their preferred form of allergy
medication (Table 4), most respondents in the 5 European
countries reported that they had tried tablets/pills/caplets, and
of that group, a majority expressed preference for this form. In
France, for example, 77% had taken tablets and 54% preferred
them, followed by the United Kingdom with 75% reporting
use and 53% expressing preference. Both German and Italian
responders had used nasal sprays in larger percentages than
tablets (71% and 52%, respectively), but neither group pre-
ferred nasal sprays to tablets. Twenty to 48% of respondents
across countries also reported having tried eye drops. Much
smaller percentages of responders had tried other vehicles of
administration (eg, syrups, throat spray, liquid gels).
FIGURE 5. Impact of allergies on sleep.
TABLE 3. Ranking by Country of Lifestyle Impact of Allergies
Function or Activity France Germany Italy Spain United Kingdom United States
BWhen I’m suffering from allergies, I find it difficult to>[
breathe normally 1 1 1 1 1 1
>get enough sleep to feel well rested in the morning 2 3 6 4 3 3
>fall asleep without trouble 3 5 3 2 5 5
>feel well rested during the day 4 4 4 3 7 2
>participate in outdoor activities 5 2 2 7 2 4
>take part in regular activities at home and at work 6 9 5 8 9 10
>sleep without snoring 7 8 11 5 10 8
>taste the food I eat 8 11 7 9 11 9
>keep my mood up and not feel unhappy or depressed 9 6 10 6 6 6
>think clearly 10 7 8 11 4 7
>take part in social activities with family and friends 11 10 9 10 8 11
>take care of my children 12 12 12 12 12 12
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Respondents from the 5 European countries answered
questions designed to identify which brands (both prescription
and OTC) they had used and which ones they had heard of and
were likely to try in the future. As a rule in all countries, the
brand that received the highest percentage of positive
responses tended to achieve the highest degree of preference
for current and future use.
Attributes listed by respondents of the ideal drug to treat
allergies were fairly consistent across all countries. Efﬁcacy,
rapid onset of action, safety, and lack of side effects were rated
as the most important attributes. Table 5 lists other desirable
qualities identiﬁed by 80% or greater of allergy sufferers from
the individual countries.
Ideal attributes of allergy medications change over time.
In US respondents, attributes that became more signiﬁcant
were relief of symptoms, recommendation by physicians and
pharmacists, freedom from sedating qualities and other
adverse effects, and not interfering with a good night’s sleep.
Some remained unchanged, such as efﬁcacy and safety, and
others became less signiﬁcant, including taste, reputation, and
use by the whole family.
Although there are many treatment options for AR, it
remains a largely undertreated condition. The percentage of
nontreaters in this survey ranged from 11% in the United
States to 21% in Germany. Reasons that respondents in this
subgroup did not treat their AR included the following:
delaying time to seek treatment because they believed that
their symptoms were unimportant, ﬁnding the cost of
medications too high, or having an inadequate relationship
with their physician or health care provider.13 Improving
communication between clinicians and patients can lead to
greater use of therapeutic interventions that will aid in
symptom relief.13
DISCUSSION
The information gathered from allergy sufferers through
the present survey supports the observations of many
clinicians that people with AR perceive their symptoms as
causing signiﬁcant QoL disruptions. Allergic rhinitis has an
unquestionable impact on QoL, including limitations on daily
activity and decreased productivity at work and school.
The information provided by QoL questionnaires
focusing on AR has also made it clear that patients with AR
are impaired in many domains of their daily lives.13 Symptoms
of AR are generally most prevalent in the morning, leading to
problems throughout the day. In 2005, Long conducted a
survey of 1000 adults with AR; 65% had symptoms upon
awakening and 83% of respondents had symptoms throughout
the morning.14 Forty-nine percent of those surveyed said that
their AR was at its worst in the morning. In the subgroup of
those who experienced symptoms on awakening, 80% felt less
energetic, 77% more fatigued, 75% less motivated, and 74%
more irritable than usual.14 In the present survey, participants
reported that all symptoms were most severe when they ﬁrst
woke up in the morning or during other times in the morning.
Respondents in all countries said they had experienced
difﬁculty in falling asleep. Sleep disturbances are commonly
noted in patients with AR and contribute to a reduction in
QoL.15 One survey involving nearly 5000 subjects with AR
found that those who frequently had symptoms at night were
signiﬁcantly more likely to report habitual snoring, chronic
excessive daytime sleepiness, or chronic nonrestorative sleep
(P G 0.0001).16 A smaller study comparing subjects with
TABLE 4. Medications Used by Respondents (%)*
Form France Germany Italy Spain United Kingdom
Tablets/pills/caplets 77/54 59/38 51/34 42/32 75/53
Nasal spray 53/12 71/35 52/25 30/20 56/21
Eye drops 41/18 48/10 42/14 20/9 43/12
Capsules 6/1 24/6 10/4 16/8 21/7
Syrups/liquids 18/3 13/1 11/4 12/7 15/3
Throat spray 24/5 12/2 19/8 16/8 14/2
Chewable 3/0 5/2 3/1 2/1 6/1
Quick-dissolve tabs 11/4 12/1 7/3 20/12 5/2
Liquid gels 1/1 13/6 6/4 5/2 2/0
Granules 26/12 4/0 3/1 2/1 1/0
*The ﬁrst number is the percentage of respondents who have tried each form; the
second number is the percentage of respondents who prefer that form.
TABLE 5. Desirable Qualities of Allergy Medications
France Germany Italy Spain* United Kingdom
&BPuts me in control of my
allergies[




&BPuts me in control of my allergies[ &BPuts me in control of my allergies[
&BDoesn’t make me drowsy[ &BProvides the right
duration of relief[
&BRelieves congestion and lets me
eat, sleep, and breathe[
&BDoesn’t make me drowsy[
&BA leader in allergy relief[ &BDoesn’t make me
drowsy[
&BLets me fall asleep[ &BAllows me to stay alert and
focused[
&BAllows me to stay alert and
focused[
&BPuts me in control of
my allergies[
&BLets me get a good night’s sleep[ &BRelieves congestion and lets me
eat, sleep, and breathe[
&BLets me wake up symptom
free[
&BLets me wake up
symptom free[
&BDoctor-recommended brand[ &BProvides full 24-hour relief[
&BProvides all-day relief into
the next morning[
&BProvides the right duration of
relief[
&BLets me wake up symptom free[
&BCan feel it working[ &BWorks on multiple symptoms[
&BLets me taste my food[
*No attribute was rated by more than 45% of respondents; attributes listed here had a 40% or greater response rate.
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seasonal AR (SAR) with healthy volunteers found a
statistically signiﬁcant relation between nighttime sleep
disruption and daytime sleepiness in those with SAR (P =
0.048). However, the daytime sleepiness could be related to
the SAR symptoms as well as the impaired sleep.17
A recent 2-week study of 483 subjects with AR
randomized to desloratadine 5 mg or placebo found that
treatment with the second-generation antihistamine deslorata-
dine signiﬁcantly improved total RQLQ scores between
baseline and day 14 (P = 0.0003 vs placebo). Signiﬁcant
decreases in RQLQ subdomain scores were also seen with
desloratadine.18 In another 2-week study of subjects with SAR
(N = 688), fexofenadine 120 mg therapy led to signiﬁcant
improvements in overall QoL, as measured by the RQLQ (P e
0.005 vs placebo).19
Given the pervasive adverse effects of AR on function
and capacity, it is evident that medical treatment for AR should
address issues beyond clinical outcome measures. One of the
chief goals of therapy is to improve patients’ well-being and
their ability to function. Treatment modalities should not only
provide optimum clinical beneﬁts; they should also increase
patient satisfaction.20,21 The allergy treatment outcome that
survey respondents in all countries desired most was the
ability to breathe normally; getting restorative sleep was
ranked second and feeling well rested during the day third.
Attributes of the ideal AR medication identiﬁed by respon-
dents in most countries included rapid onset of action, safety,
and minimal bothersome side effects.
Responses to the survey suggest that AR is often
perceived as causing daytime fatigue. It is possible that some
people with AR could be experiencing the sedating effects of
ﬁrst-generation antihistamines in addition to the impairment
and sleep disturbances caused by their symptoms.
Although not speciﬁcally addressed by the survey
administrators, it should be noted that there are differences
among the 5 European countries in allergenic pollens. Grass,
birch, mugwort, and ragweed pollen predominate in central
Europe and in mountainous areas, whereas olive, cypress, and
plants in the genus Parietaria dominate in the Mediterranean
region.22 Although pollen seasons tend to be shorter in
northern climates with colder weather, allergy severity varies
from year to year depending on weather patterns, especially
rainfall. Due to higher pollution levels, populations in more
urbanized regions and countries will experience greater
sensitivity to allergens.22 These factors may help to explain
the variation between countries seen in this survey and those
recently reported in a broader range of countries.23
CONCLUSIONS
Results from this survey highlight the range of allergic
symptoms that negatively impact the lifestyle of people with
AR. Patients clearly want treatment options that improve their
QoL and restore their ability to engage in activities of daily
living.
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